EHSI completes Celulas Genetica acquisition

Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.

“Celulas Genetica's license to develop and market the Rutherford Procedure was our main motivator to complete this acquisition”

EHSI initially signed a profit participation agreement with the company in March. Headquartered in Panama City, Panama, Celulas Genetica is a Central American leader in stem-cell technology acquisition and development. Earlier this week, the company purchased a license to develop and market the revolutionary Rutherford Procedure, a groundbreaking organ regeneration treatment designed to use proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells.

"Celulas Genetica's license to develop and market the Rutherford Procedure was our main motivator to complete this acquisition," said EHSI President and CEO Cindy Morrissey. "We intend to test this innovative procedure thoroughly and develop it into a viable treatment for deadly illnesses such as liver disease. The worldwide demand for stem-cell therapies of this kind is extraordinary."

For more information on Celulas Genetica, visit http://www.TheStemCellGroup.com.

Celulas Genetica will be only the latest outpost in Emerging Healthcare Solutions' global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland.

"Much of the top stem-cell research being conducted today takes place outside the United States," Morrissey said. "To be an industry leader in this field, you have to be international, and we fully intend to fund and produce industry-leading innovations."

EHSI invests in technology developed to compete in the stem-cell research industry alongside Celgene Corporation (NASDAQ:CELG), Gilead Sciences Inc. (NASDAQ:GILD), Life Technologies Corporation (NASDAQ:LIFE) and Illumina Inc. (NASDAQ:ILMN).